[The chemotherapeutic treatment of advanced Hodgkin's disease]
| Autor: | R, Epelbaum, N, Haim, M, Ben-Shahar, I, Valtuch, D, Faraggi, A, Sharabi-Nov, Y, Ben-Arie, Y, Cohen |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Aged 80 and over Male Adolescent Middle Aged Vinblastine Combined Modality Therapy Hodgkin Disease Disease-Free Survival Dacarbazine Survival Rate Bleomycin Doxorubicin Vincristine Procarbazine Antineoplastic Combined Chemotherapy Protocols Multivariate Analysis Humans Prednisone Female Mechlorethamine Aged Retrospective Studies |
| Zdroj: | Harefuah. 140(4) |
| ISSN: | 0017-7768 |
| Popis: | Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. The median age was 35 years, 58% had stage III and 42% had stage IV disease. Failure-free survival at 10 years was 43.9%. It was 66.7%, 48.4% and 29.9% for patients treated by M/A, M-A and M, respectively. Overall survival at 10 years was 40.8%, and 78.2%, 48% and 27.7% for patients treated by M/A, M-A and M, respectively. Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors. M/A combination was more myelotoxic, while M combination caused more second primaries. Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|